| dc.contributor.author | Newton, G | |
| dc.contributor.author | Lord, C | |
| dc.contributor.other | Ashworth, A | |
| dc.contributor.other | Perrior, T | |
| dc.coverage.spatial | International | |
| dc.date.accessioned | 2020-08-19T10:05:11Z | |
| dc.date.issued | 2013-02-21 | |
| dc.identifier | GB2012051978W | |
| dc.identifier | WO2013024282 | |
| dc.identifier.citation | 2013 | |
| dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/3990 | |
| dc.description.abstract | The invention provides a compound that is an inhibitor of one or both of TBK1 and IKKe, or a down-regulator of the expression of one or both of TBK1 and IKKe, for use in a method of treating a cancer that is dependent on the PI3kinase pathway. The invention further provides a method of treating cancer in an individual in whom the cancer is dependent on the PI3kinase pathway, comprising administering to the individual a compound that is an inhibitor of one or both of TBK1 and IKKe, or a down-regulator of the expression of one or both of TBK1 and IKKe. | |
| dc.language | eng | |
| dc.language.iso | eng | |
| dc.subject | Kinase | |
| dc.subject | Oncology | |
| dc.title | COMPOUNDS AND THEIR USES | |
| dc.type | Patent | |
| rioxxterms.licenseref.startdate | 2013-02-21 | |
| rioxxterms.type | Other | |
| pubs.filed-date | 2012-08-14 | |
| pubs.notes | Not known | |
| pubs.organisational-group | /ICR | |
| pubs.organisational-group | /ICR/Primary Group | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research/Gene Function | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicinal Chemistry 3 | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Gene Function | |
| pubs.organisational-group | /ICR | |
| pubs.organisational-group | /ICR/Primary Group | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research/Gene Function | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicinal Chemistry 3 | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Gene Function | |
| pubs.patent-status | PCT | |
| pubs.embargo.terms | Not known | |
| icr.researchteam | Medicinal Chemistry 3 | en_US |
| icr.researchteam | Gene Function | en_US |
| dc.contributor.icrauthor | Newton, Gary | en |
| dc.contributor.icrauthor | Lord, Christopher | en |
